| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yuan Xie, Yan Jiang, Xiao-bo Yang, An-qiang Wang, Yong-chang Zheng, Xue-shuai Wan, Xin-ting Sang, Kai Wang, Da-dong Zhang, Jia-jia Xu, Fu-gen Li and Hai-tao Zhao |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| International Science and Technology Cooperation Projects |
2015DFA30650 |
| International Science and Technology Cooperation Projects |
2010DFB33720 |
| Capital Special Research Project for Health Development |
2014-2-4012 |
| Capital research project for the characteristics clinical application |
Z151100004015170 |
|
| Corresponding Author |
Hai-tao Zhao, MD, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Shuaifuyuan, Wangfujing, Beijing 100730, China. zhaoht@pumch.cn |
| Key Words |
BRCA; Mutation; Olaparib; Poly ADP-ribose polymerase inhibitor; Gallbladder cancer |
| Core Tip |
Gallbladder cancer (GBC) is the most common neoplasm of the biliary tract system. BRCA1, the first major breast cancer susceptibility gene, has been widely studied in breast and ovarian cancers. Olaparib, an oral poly ADP-ribose polymerase (PARP) inhibitor, has been approved by FDA and European commission for the treatment of ovarian cancer with any BRCA1/2 mutations. However, there is no report of germline BRCA1 functional mutation in GBC prior to this case. Even further the GBC with BRCA1 mutation responded to PARP inhibitor olaparib. |
| Publish Date |
2016-12-13 00:40 |
| Citation |
Xie Y, Jiang Y, Yang Xb, Wang Aq, Zheng Yc, Wan Xs, Sang Xt, Wang K, Zhang Dd, Xu Jj, Li Fg, Zhao Ht. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016; 22(46): 10254-10259 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i46/10254.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i46.10254 |
